Clinical Trial

Question Prompt List in Breast Cancer Patients Planned for Neoadjuvant Chemotherapy

Study acronym: QPL
Recruiting
View on ClinicalTrials.gov →
Summary
Preoperative chemotherapy has been shown to be at least as effective as postoperative chemotherapy in breast cancer patients and has seen increased use over time. The decision regarding neoadjuvant treatment is complex, as various aspects need to be considered, and the patient's role in the decision-making process is central. The information provided by doctors to patients about preoperative treatment can be complicated, including details about treatment options, treatment plans, and side effects. If this information is not conveyed adequately, there is a risk of misunderstandings, which can lead to increased anxiety and stress for patients regarding their decisions. In oncology, question prompt lists (QPL) have been used as a tool to support patients by improving the information conveyed by doctors in various contexts where complex decisions need to be made. Studies have shown that QPL can facilitate better information exchange. However, their use in discussions about preoperative treatment for breast cancer patients has not been studied. Furthermore, evidence from randomized studies on the use of QPL in clinical practice is very limited. The aim of this study is to investigate whether the use of QPL during patient consultations involving discussions about neoadjuvant chemotherapy can improve information exchange in various aspects: understanding of the treatment; anxiety about the decision; participation in the decision-making process; patient-doctor communication; and decision-related conflict.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-10.
Status change: Not Yet Recruiting → Recruiting 2025-04-16
Trial Details
NCT Number NCT06777420
Lead Sponsor Region Örebro County
Conditions Breast Cancer Early Stage Breast Cancer (Stage 1-3), Neoadjuvant Therapy, Shared Decision Making
Enrollment 218 participants
Start Date 2025-03-01
Primary Completion 2027-01 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2025-04-20